1414943-88-6

Basic information

• Product Name: BAY-1143572.
• Synonyms: BAY 1143572;BAY1143572;BAY-1143572.;4-(4-fluoro-2-methoxyphenyl)-N-(3-((S-methylsulfonimidoyl)methyl)phenyl)-1,3,5-triazin-2-amine
• CAS NO: 1414943-88-6
• Molecular Formula: C₁₈H₁₈FN₅O₂S
• Molecular Weight: 387.4312232
• Mol File: 1414943-88-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 589.9±60.0 °C(Predicted)
• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• CAS DataBase Reference: BAY-1143572.(CAS DataBase Reference)
• NIST Chemistry Reference: BAY-1143572.(1414943-88-6)
• EPA Substance Registry System: BAY-1143572.(1414943-88-6)

Safety Data

• Hazardous Substances Data: 1414943-88-6(Hazardous Substances Data)

Usage

Description

BAY-1143572 is a chemical compound that belongs to the class of protein kinase inhibitors. It functions by specifically targeting and inhibiting the activity of proteins that drive the growth and spread of cancer cells. BAY-1143572. has demonstrated potential in preclinical studies for treating various cancer types, such as lung and pancreatic cancer, and is currently under evaluation in clinical trials to assess its safety and efficacy in cancer patients.

Uses

Used in Oncology:
BAY-1143572 is used as an anticancer agent for its ability to inhibit the growth and spread of cancer cells by targeting specific proteins involved in these processes. It has shown promise in preclinical studies for the treatment of various types of cancer, including lung and pancreatic cancer.
Used in Clinical Trials:
BAY-1143572 is used in clinical trials to determine its safety and effectiveness in treating cancer patients. These trials are crucial for establishing the therapeutic potential of the compound and identifying any possible side effects or risks associated with its use.
Used in Cancer Research:
BAY-1143572 is used as a subject of research to further explore its therapeutic potential and to understand the mechanisms by which it inhibits cancer cell growth and spread. Ongoing research aims to identify additional cancer types that may benefit from treatment with BAY-1143572 and to optimize its use in combination with other cancer therapies.
Used in Drug Development:
BAY-1143572 is used in the development of new cancer treatments, as it represents a novel approach to targeting the proteins responsible for cancer progression. Its potential as a protein kinase inhibitor makes it a valuable candidate for further development and optimization in the quest for more effective cancer therapies.

Upstream product

• 1415249-81-8 4-(4-fluoro-2-methoxyphenyl)-N-{3-[(methylsulfanyl)methyl]phenyl}-1,3,5-triazin-2-amine 
• 1415249-80-7 4-chloro-N-{3-[(methylsulfanyl)methyl]phenyl}-1,3,5-triazin-2-amine 
• 90607-33-3 3-[(methylsulfanyl)methyl]aniline 
• 1415250-23-5 4-(4-fluoro-2-methoxyphenyl)-N-{3-[(S-methylsulfinyl)methyl]phenyl}-1,3,5-triazin-2-amine 
• 1414944-24-3 (rac)-ethyl [{3-[(4-chloro-1,3,5-triazin-2-yl)amino]benzyl}(methyl)-oxido-λ⁶-sulfanylidene]carbamate 
• 1414944-22-1 (rac)-ethyl [(3-aminobenzyl)(methyl)oxido-λ⁶-sulfanylidene]carbamate 
• 1414944-20-9 (rac)-ethyl [methyl(3-nitrobenzyl)oxido-λ⁶-sulfanylidene]carbamate 
• 1414944-15-2 (rac)-2,2,2-trifluoro-N-[methyl(3-nitrobenzyl)oxido-λ⁶-sulfanylidene]acetamide 
• 1414943-84-2 (rac)-ethyl [(3-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ⁶-sulfanylidene]carbamate 
• 619-23-8 3-Nitrobenzyl chloride 
• 51392-54-2 1-[(methylsulfanyl)methyl]-3-nitrobenzene 

Downstream Products

• 1415248-79-1 (rac)-N-{3-[(N,S-dimethylsulfonimidoyl)methyl]phenyl}-4-(4-fluoro-2-methoxyphenyl)-l,3,5-triazin-2-amine 
• 1415248-46-2 (rac)-1-[(3-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ6-sulfanylidene]-3-methylurea 
• 1415248-88-2 (rac)-4-{2-[(4-fluorobenzyl)oxy]phenyl}-N-{3-[(S-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine 
• 1415248-54-2 (rac)-N-[(3-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}benzyl)(methyl)oxido-λ6-sulfanylidene]acetamide 

Relevant articles and documents

Synthesis of NH-Sulfoximines by Using Recyclable Hypervalent Iodine(III) Reagents under Aqueous Micellar Conditions

The synthesis of NH-sulfoximines from sulfides has been first developed under mild conditions in an aqueous solution with surfactant TPGS-750-M as the catalyst at room temperature. In this newly developed process, a simple and convenient recycling strategy to regenerate the indispensable hypervalent iodine(III) is used. The resulting 1,2,3-trifluoro-5-iodobezene can be recovered almost quantitively from the mixture by liquid–liquid extraction and then oxidized to give the corresponding iodine(III) species. This optimized procedure is compatible with a broad range of functional groups and can be easily performed on a gram scale, providing a green protocol for the synthesis of sulfoximines.

Palladium-Catalyzed Direct α-Arylation of p -Methoxybenzyl-Protected S, S -Dimethylsulfoximine

Sulfoximines have recently gained considerable recognition as an important structural motif in the life sciences. This is especially true for (hetero)aryl-substituted S,S-dimethylsulfoximine derivatives, such as the marketed insecticide sulfoxaflor, as well as the clinical candidates PTEFb inhibitor BAY 1143572 and ATR inhibitor AZD 6738 for the treatment of cancer. Herein, the first palladium-catalyzed direct α-arylation of p-methoxybenzyl-protected S,S-dimethylsulfoximine using readily available (hetero)aryl bromides is reported. This new method provides a safe, short, and efficient approach to (hetero)aryl-substituted S,S-dimethylsulfoximine derivatives, an important class of bioactive compounds, demonstrated by application of this methodology to an improved synthesis of PTEFb inhibitor BAY 1143572.

4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES CONTAINING A SULFOXIMINE GROUP

The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).